Record €2.3 billion fundraising will support around 30 biotech companies
BioSpace reports on Forbion’s €2.3 billion ($2.6 billion) fundraising across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The raise is Forbion’s largest to date, bringing assets under management to approximately €7.5 billion and creating capacity to support around 30 companies.
The article highlights Forbion’s focus on high-quality life sciences companies developing novel therapeutics for areas of significant unmet medical need. The two funds support this strategy at different stages: Ventures Fund VIII will build, invest in and support innovative biotech companies, particularly at the preclinical and early clinical stages, while Growth Opportunities Fund IV will provide growth capital to companies scaling their businesses.
With a portfolio of more than 140 companies, Forbion continues to invest selectively in ambitious teams and promising science with the potential to advance medicine and deliver lasting impact.